Efficacy of sequential denosumab after teriparatide for 6 months compared with denosumab monotherapy in reducing risk of osteoporotic fractures in patients with new fractures: a multicentre randomised controlled trial (STAND study) protocol

What Was Tested

This clinical study looks at Teriparatide.

The study protocol has been registered on ClinicalTrials.gov and has received ethical approval from the Peking Union Medical College Hospital Medical Science Research Ethics Committee (1-22PJ939).

The findings will be disseminated through peer-reviewed scientific journals.

Who Took Part

The abstract describes 2478 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This study is designed as a multicentre, open-label, randomised controlled trial among 2478 patients with newly diagnosed osteoporotic fractures from 58 hospitals across China.

Follow-up assessments are scheduled at 3, 6, 9, 12, 18 and 24 months post-randomisation for primary and secondary outcomes, and biannually afterwards for the primary outcome.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Teriparatide study did not mask who received what.

More than one site took part, so the patients came from several places.

What Was Measured

Topics PubMed links to this paper include Denosumab, Teriparatide, Bone Density Conservation Agents, Osteoporotic Fractures, Bone Density, Randomized Controlled Trials as Topic and Osteoporosis.

The authors tagged it with the keywords Calcium & bone, Disease Management, Drug Therapy and Health Care Costs.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Teriparatide in 2478 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2026 (BMJ open), a journal based in England.

More context: the Teriparatide compound page, all human trials.